DSCSA 2024 Enhanced Drug Distribution Security
Drug Supply Chain Security Act 2024 Stabilization and Enhanced Drug Distribution Security · Drug Supply Chain Security Act · DSCSA · EDDS · EPCIS 1.2 · VRS · Verification Router Service · saleable returns
Term — DSCSA enhanced drug distribution security and the 2024 stabilisation period: dSCSA EDDS framework — package-level Standardized Numerical Identifier (sGTIN in 2D DataMatrix with lot/expiration), EPCIS 1.2 trading-partner event sharing (commissioning, packing, shipping, receiving, dispatching, decommissioning, aggregation, transformation), Verification Router Service for saleable-returns verification, Authorised Trading Partner discipline, suspect/illegitimate-product investigation with Form FDA 3911, FDA stabilization extending compliance through November 2024 for manufacturers/wholesalers, dispenser exemptions through November 2025/2026.
Drug Supply Chain Security Act (Title II of Drug Quality and Security Act 2013) 10-year framework for interoperable electronic package-level prescription drug traceability. Standardized Numerical Identifier per saleable package — GS1 Serialised GTIN (sGTIN-14 plus unique serial) as 2D DataMatrix with lot and expiration. Aggregation links unit-case-pallet via SSCC for inference at receiving. EPCIS 1.2 events — Object Event (commissioning, decommissioning, shipping, receiving), Aggregation Event (parent-child), Transaction Event (linking objects to business transactions), Transformation Event (repackaging) — each with event time, action ADD/OBSERVE/DELETE, business step, disposition, EPC list, business transaction list, source/destination master data. Location Master Data (GLN) and Product Master Data (GTIN, NDC) cross-partner alignment is the dominant data-quality issue. Transaction-level data — Transaction Information (TI), Transaction History (TH), Transaction Statement (TS). Verification Router Service for saleable-returns — wholesaler queries with GTIN/serial/lot/expiration, VRS routes to manufacturer verification system, response within 2-30 seconds. Authorised Trading Partner — manufacturers (FDA registered), repackagers, wholesale distributors (state license + NABP Drug Distributor Accreditation), dispensers (state pharmacy license); verification at onboarding and material change. Suspect product framework (Section 582) — quarantine and investigate within 24-72 hours, if illegitimate notify FDA via Form FDA 3911 within 24 hours and notify immediate trading partners. Original effective date November 27, 2023; FDA stabilization compliance policy August 2023 extended enforcement to November 27, 2024 for manufacturers/repackagers/wholesalers/dispensers; further extension to November 27, 2025 for non-small dispensers and November 27, 2026 for small dispensers (≤25 FTE). 503A compounding generally exempt; 503B outsourcing partially exempt. Veterinary drugs not subject. Industry guidance includes GS1 US Healthcare DSCSA EPCIS Implementation Guideline and HDA reference architecture.
- Drug Quality and Security Act 2013 Title II
- 21 USC §360eee
- FDA Compliance Policy August 2023
- FDA Compliance Policy October 2024
Try V5 free for 7 days with no card needed, or talk to our team about what applies to your operation.